An Osteoconductive Matrix
Ousia bioXEN is a naturally sourced bovine bone mineral. The unique manufacturing process of bioXEN results in a bone grafting particulate with the crystalline structure of carbonate apatite, which is a structure similar to intact human bone. In addition, the manufacturing process for bioXEN allows for a combination of a porous structure for vascular access with a roughened surface that is favorable to cell adhesion and subsequent bone matrix deposition.
Ousia bioXEN allows the clinician to have available a safe and biocompatible osteoconductive matrix that can be used for new bone formation in defects.
BONE GRAFT PARTICULATE
PASS or Fail (1)
Living bone is dynamic, a balanced process of bone formation and bone resorption. For bone to properly regenerate, there are several conditions that should be met.
- Primary wound closure
- Space maintenance
- Stability of wound area and implant
Ousia bioXEN addresses the need for a biocompatible, safe, and effective osteoconductive matrix. This matrix, combined with a well vascularized site and containment of the bioXEN particulate, provides a scaffold for the natural process of bone development. The inclusion of Ousia bioMAINTAIN or bioADAPT barrier membranes allows for site protection from undesired soft tissue ingrowth.
Ousia bioXEN indications:
- Reconstruction of the alveolar ridge
- Periodontal defects
- Extraction sockets
- Sinus elevations
- Procedures involving guided bone or guided tissue regeneration
Ousia bioXEN benefits:
- Easy handling of material allows for precise graft placement
- Osteoconductive scaffold is favorable to bone formation
- Porosity of material allows for thorough revascularization
- Particle structure helps to maintain space
bioXEN and BioOss® sections taken at 2 months, show residual implant material present within the defects. The histology images shown below refer to new bone in apposition to the bioXEN or Bio-Oss® bone mineral matrix. New bone (green) can also be seen adjacent to the mineral showing evidence of ongoing bone formation in the defect area.
In vivo studies comparing Ousia bioXEN and Bio-Oss®, show the similarities in performance of these products. In this study, there were no significant differences between the two products. (2)
Histological Assessment at 8 Weeks
(1) PASS Principles for Predictable Bone Regeneration.
Wang, HL and Boyapati, L; Department of Periodontics and Oral Medicine, School Dentistry, University of Michigan.
(2) Data on file.
Bio-Oss® is a registered trademark of Geistlich, Wolhusen, Switzerland.